Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExtendicareEXETF -0.14%69 Intrinsic Value: Projected FCF is $6.14 as of Sep. 01, 2026. GuruFocus rates EXETF with a GF Score™ of 69/100 and a GF Value™ of $11.64 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 343 Healthcare Providers & Services companies, Extendicare ranks worse than 86.01% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-01), Extendicare's Intrinsic Value: Projected FCF is $6.14. The stock price of Extendicare is $22.722. Therefore, Extendicare's Price-to-Intrinsic-Value-Projected-FCF of today is 3.7.
The historical rank and industry rank for Extendicare's Intrinsic Value: Projected FCF or its related term are showing as below:
EXETF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 2.23 Med: 3.66 Max: 48.53
Current: 3.7
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Extendicare was 48.53. The lowest was 2.23. And the median was 3.66.
EXETF's Price-to-Projected-FCF is ranked worse than 86.01% of 343
companies
in the Healthcare Providers & Services industry
Industry Median: 1.09
vs EXETF: 3.70
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Extendicare's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
22.722
/
6.0740040855773
=
3.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extendicare Intrinsic Value: Projected FCF Related Terms
Extendicare Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Extendicare's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EXETF vs HCA, THC, EHC: Intrinsic Value: Projected FCF Comparison
For the Medical Care Facilities subindustry, Extendicare's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extendicare Price-to-Projected-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Extendicare's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Extendicare's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $6.14 mean?
Extendicare (EXETF) has a Intrinsic Value: Projected FCF of $6.14 as of Sep. 01, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Extendicare and its competitors. According to the industry distribution chart, Extendicare ranks #295 out of 343 companies in the Healthcare Providers & Services industry, placing it in the top 86%.
Is Extendicare's Intrinsic Value: Projected FCF too high?
Extendicare's current Intrinsic Value: Projected FCF is $6.14. The Healthcare Providers & Services industry median Intrinsic Value: Projected FCF is 1.09. Extendicare's value of $6.14 is 463.3% above this industry median. Based on the distribution chart, Extendicare ranks #295 out of 343 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Extendicare has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Extendicare's Intrinsic Value: Projected FCF compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Extendicare ranks #295 out of 343 companies for Intrinsic Value: Projected FCF. This places Extendicare in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.09. Extendicare's value of $6.14 is 463.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Healthcare Providers & Services company?
The median Intrinsic Value: Projected FCF among Healthcare Providers & Services companies is 1.09, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Extendicare's current Intrinsic Value: Projected FCF of $6.14 is 463.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Extendicare and its competitors. For the Healthcare Providers & Services industry, the median Intrinsic Value: Projected FCF is 1.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extendicare's current Intrinsic Value: Projected FCF is $6.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extendicare stock overvalued right now?
Based on GuruFocus' analysis, Extendicare (EXETF) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.64, compared to a current price of $22.72 — trading 95.2% above its estimated fair value. The current Intrinsic Value: Projected FCF is $6.14 and 463.3% above the Healthcare Providers & Services industry median of 1.09. Extendicare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Extendicare (EXETF), the current Intrinsic Value: Projected FCF is $6.14 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Extendicare (EXETF) Overvalued in 2026?
Based on GuruFocus' analysis, Extendicare stock appears to be overvalued.
The current stock price of $22.72 is trading 95.2% above its estimated GF Value™ of $11.64.
GuruFocus considers Extendicare to be Significantly Overvalued.
Key valuation signals for EXETF:
Intrinsic Value: Projected FCF: $6.14
GF Value™: $11.64 vs. price of $22.72 (95.2% above fair value)
Industry Position: 463.3% above the Healthcare Providers & Services median (#295 of 343)
No single metric tells the full story. See the EXETF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.
69GF Score
Get the complete analysis for EXETF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EXETF has been successfully added to your 
